| Trial ID: | L3264 |
| Source ID: | NCT04657939
|
| Associated Drug: |
Liraglutide
|
| Title: |
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
|
| Acronym: |
Lean-DM
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Liraglutide|DRUG: Pioglitazone
|
| Outcome Measures: |
Primary: Change in myocardial perfusion after treatment, Measured changes in myocardial perfusion by Magnetic Resonance Imaging (MRI) after treatment with liraglutide and pioglitazone., 40 weeks | Secondary: Myocardial energetics (PCr/ATP ratio), Change in myocardial energetics as measured by MRI after treatment, 40 weeks|Myocardial steatosis (myocardial triglyceride content), Change in myocardial steatosis as measured by MRI after treatment, 40 weeks|Myocardial function, Change in myocardial function as measured by MRI after treatment, 40 weeks|Insulin resistance (HOMA-IR), Change in HOMA-IR as determined by blood results after treatment, 40 weeks|Physical performance, Change in physical performance as measured by 6 minute walk test after treatment, 40 weeks|Hepatic steatosis (hepatic triglyceride content), Change in hepatic steatosis as measured by MRI after treatment, 40 weeks|Peripheral endothelial function, Changes in peripheral endothelial function as measured by EndoPAT after treatment, 40 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Leeds
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
57
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-12-01
|
| Completion Date: |
2022-10-31
|
| Results First Posted: |
|
| Last Update Posted: |
2023-02-27
|
| Locations: |
Leeds Teaching Hospitals Trust, Leeds, West Yorkshire, LS1 3EX, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT04657939
|
